HomeDiscoveryPipelineA602 project (Danusertib)

A602 project (Danusertib)

Danusertib is a potent pan-inhibitor of Aurora mitotic kinases, which has conducted Phase I and II clinical trials as single agent and in combination in solid tumors and haematological malignancies. The drug has good PK properties and a manageable safety profile. More recent literature data and in house preclinical studies indicate that Danusertib may be efficacious in selected tumors, such as those with Myc overexpression, supporting this setting as a potential new clinical indication.